SRACE is an multicenter observational database of outcomes for patients who are hospitalized with an acute coronary events. SRACE includes over 20 hospitals in Shanghai China that have enrolled a total of more than 3,000 patients since 2005, with an annual enrollment of 500 patients. The major purpose of the SRACE program is to evaluate the prognosis of patients admitted to the hospital due to acute coronary events, comparing different therapeutic strategies, in-hospital transferring system, and so on. All participating physicians receive confidential quarterly reports showing ther outcomes side-by-side with the aggregate outcomes of all participating hospitals.
consecutive patients with STEMI who presented symptoms within 12 hours and treated by primary PCI in Shanghai, were enrolled in the prospective sysytem. Several strategies were applied in these patients, including physician vs. patient transfer strategy, upsteam vs. downstream strategy, Firebird stent vs. Excel stent (bio-absorbable SES), etc. Once the patient was randomized to one of these study, he will be denied to the others. Clinical and angiographic outcomes were compared, with the final purpose to find an optimal strategy in treating AMI patients.
Study Type
OBSERVATIONAL
Enrollment
20,000
drug-eluting stent, including sirolimus-eluting, paclitaxel-eluting and other types of China-made drug-eluting stent
upstream (in emergency room) versus downstream (in catheterization lab) intra-coronary loading versus conventional intravenous loading
Dept. of Cardiology, Ruijin Hospital
Shanghai, Shanghai Municipality, China
major adverse cardiac events(MACE), including death, non-fatal re-MI, and target vessel revascularization
Time frame: in-hospital, 30d, and long-term follow-up
stroke, stent thrombosis
Time frame: in-hospital, 30d, and long-term follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.